CDTXCidara Therapeutics, Inc.

Nasdaq cidara.com


$ 12.38 $ -0.33 (-2.6 %)    

Thursday, 16-May-2024 10:19:09 EDT
QQQ $ 454.54 $ 1.07 (0.24 %)
DIA $ 400.85 $ 1.57 (0.39 %)
SPY $ 531.31 $ 1.38 (0.26 %)
TLT $ 92.38 $ -0.01 (-0.01 %)
GLD $ 219.70 $ -0.30 (-0.14 %)
$ 12.71
$ 12.38
$ 0.00 x 0
$ 0.00 x 0
$ 12.38 - $ 12.38
$ 10.00 - $ 29.60
22,090
na
57.68M
$ 1.24
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-15-2024 03-31-2024 10-Q
2 04-22-2024 12-31-2023 10-K
3 11-02-2023 09-30-2023 10-Q
4 08-03-2023 06-30-2023 10-Q
5 05-11-2023 03-31-2023 10-Q
6 03-23-2023 12-31-2022 10-K
7 11-03-2022 09-30-2022 10-Q
8 08-09-2022 06-30-2022 10-Q
9 05-11-2022 03-31-2022 10-Q
10 03-07-2022 12-31-2021 10-K
11 11-10-2021 09-30-2021 10-Q
12 08-12-2021 06-30-2021 10-Q
13 05-13-2021 03-31-2021 10-Q
14 02-25-2021 12-31-2020 10-K
15 11-05-2020 09-30-2020 10-Q
16 08-13-2020 06-30-2020 10-Q
17 05-13-2020 03-31-2020 10-Q
18 03-04-2020 12-31-2019 10-K
19 11-08-2019 09-30-2019 10-Q
20 08-08-2019 06-30-2019 10-Q
21 05-09-2019 03-31-2019 10-Q
22 02-28-2019 12-31-2018 10-K
23 11-08-2018 09-30-2018 10-Q
24 08-09-2018 06-30-2018 10-Q
25 05-10-2018 03-31-2018 10-Q
26 02-27-2018 12-31-2017 10-K
27 11-08-2017 09-30-2017 10-Q
28 08-09-2017 06-30-2017 10-Q
29 05-10-2017 03-31-2017 10-Q
30 03-15-2017 12-31-2016 10-K
31 11-10-2016 09-30-2016 10-Q
32 08-11-2016 06-30-2016 10-Q
33 05-12-2016 03-31-2016 10-Q
34 03-18-2016 12-31-2015 10-K
35 11-16-2015 09-30-2015 10-Q
36 08-11-2015 06-30-2015 10-Q
37 05-21-2015 03-31-2015 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 needham-reiterates-buy-on-cidara-therapeutics-maintains-25-price-target

Needham analyst Joseph Stringer reiterates Cidara Therapeutics (NASDAQ:CDTX) with a Buy and maintains $25 price target.

 cidara-therapeutics-q1-2024-gaap-eps-228-misses-020-estimate-sales-846m-beat-630m-estimate

Cidara Therapeutics (NASDAQ:CDTX) reported quarterly losses of $(2.28) per share which missed the analyst consensus estimate of...

 wbb-securities-maintains-strong-buy-on-cidara-therapeutics-adjusts-price-target-to-40-reverse-stock-split---120

WBB Securities analyst Stephen Brozak maintains Cidara Therapeutics (NASDAQ:CDTX) with a Strong Buy, adjusts target to $40 (rev...

 needham-maintains-buy-on-cidara-therapeutics-adjusts-price-target-to-25

Needham analyst Joseph Stringer maintains Cidara Therapeutics (NASDAQ:CDTX) with a Buy, adjusts target to $25 from $3.

 cantor-fitzgerald-reiterates-overweight-on-cidara-therapeutics

Cantor Fitzgerald analyst Louise Chen reiterates Cidara Therapeutics (NASDAQ:CDTX) with a Overweight.

Core News & Articles
Market-Moving News for April 25th
04/25/2024 12:31:16

ULBI: 26% | Ultralife shares are trading higher after the company reported better-than-expected Q1 financial results.CDTX: 41% ...

Core News & Articles

- $240 million private placement financing led by RA Capital Management with significant participation by Bain Capital Life Sci...

 cidara-therapeutics-announces-divestiture-of-rezafungin-to-mundipharma-to-focus-on-advancing-the-clinical-development-of-cloudbreak-dfc-pipeline-transaction-provides-company-with-an-estimated-128m-in-cost-savings

Transaction provides company with an estimated approximately $128 million in cost savings, including approximately $67 million ...

 cantor-fitzgerald-reiterates-overweight-on-cidara-therapeutics

Cantor Fitzgerald analyst Louise Chen reiterates Cidara Therapeutics (NASDAQ:CDTX) with a Overweight.

 cidara-therapeutics-q4-eps-004-beats-010-estimate-sales-1758m-beat-1154m-estimate

Cidara Therapeutics (NASDAQ:CDTX) reported quarterly losses of $(0.04) per share which beat the analyst consensus estimate of $...

 cidara-therapeutics-announces-receipt-of-nasdaq-delinquency-notice

Cidara Therapeutics, Inc. (NASDAQ:CDTX) (the Company), a biotechnology company using its proprietary Cloudbreak® platform to de...

 why-cidara-therapeutics-cdtx-stock-is-falling

Cidara Therapeutics shares are trading lower by 24.4% Monday afternoon. The company announced a 1-for-20 reverse stock split.

 cidara-therapeutics-announces-1-for-20-reverse-stock-split-will-begin-trading-on-a-split-adjusted-basis-commencing-upon-market-open-on-april-24-2024

Cidara Therapeutics, Inc. (NASDAQ:CDTX) (the Company), a biotechnology company using its proprietary Cloudbreak® platform to de...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION